PerkinElmer is among the latest vendors to receive an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a reverse transcription polymerase chain reaction (RT-PCR) test for the novel coronavirus.
The agency's decision means CLIA-certified laboratories can immediately begin using the company's test kit to detect SARS-CoV-2, the virus that causes COVID-19, PerkinElmer said in a statement. The company also noted that the RT-PCR test meets the requirements of the European In Vitro Diagnostic Directive (IVDD) and is available in more than 30 countries worldwide.
